Castle Biosciences signals $385M-$395M 2026 revenue outlook as TissueCypher targets 50%-52% volume growth (NASDAQ:CSTL)
· seekingalpha.com
Castle Biosciences Q3 2026 earnings: revenue rose 24%, guidance increased, and TissueCypher drove growth.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...